Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Oncology Institute (TOI) EBIAT (2020 - 2025)

Oncology Institute's EBIAT history spans 6 years, with the latest figure at -$7.5 million for Q4 2025.

  • For Q4 2025, EBIAT rose 43.04% year-over-year to -$7.5 million; the TTM value through Dec 2025 reached -$60.6 million, up 6.27%, while the annual FY2025 figure was -$60.6 million, 6.27% up from the prior year.
  • EBIAT reached -$7.5 million in Q4 2025 per TOI's latest filing, up from -$16.5 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $19.3 million in Q1 2022 to a low of -$30.0 million in Q1 2023.
  • Average EBIAT over 5 years is -$11.0 million, with a median of -$14.3 million recorded in 2024.
  • Peak YoY movement for EBIAT: plummeted 253899900.0% in 2021, then skyrocketed 2036.35% in 2022.
  • A 5-year view of EBIAT shows it stood at -$10.2 million in 2021, then decreased by 8.38% to -$11.0 million in 2022, then plummeted by 70.38% to -$18.8 million in 2023, then grew by 29.71% to -$13.2 million in 2024, then soared by 43.04% to -$7.5 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's EBIAT are -$7.5 million (Q4 2025), -$16.5 million (Q3 2025), and -$17.0 million (Q2 2025).